Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness [Internet].

The purpose of this report is to evaluate the cost-effectiveness of denosumab and zoledronic acid for the treatment of postmenopausal women and men with osteoporosis, including women receiving adjuvant aromatase inhibitor therapy for non-metastatic breast cancer, men receiving androgen deprivation therapy for non-metastatic prostate cancer, and patients with severe renal dysfunction.

http://ift.tt/2lP8lKn